Article Information
History
- July 24, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Chansavath Phetsouphanh1,
- Weng Hua Khoo2,3,
- Katherine Jackson2,
- Vera Klemm1,
- Annett Howe1,
- Anupriya Aggarwal1,
- Anouschka Akerman1,
- Vanessa Milogiannakis1,
- Alberto Ospina Stella1,
- Romain Rouet2,
- Peter Schofield2,
- Megan L. Faulks2,
- Hannah Law1,
- Thidarat Danwilai6,
- Mitchell Starr6,
- C. Mee Ling Munier1,
- Daniel Christ2,
- Mandeep Singh2,3,
- Peter I Croucher2,
- Fabienne Brilot-Turville4,5,
- Stuart Turville1,
- Tri Giang Phan2,3,
- Gregory J Dore1,7,
- David Darley7,
- Philip Cunningham6,
- Gail V Matthews1,7,
- Anthony D Kelleher1,7,* and
- John J Zaunders6,#,*
- 1Kirby Institute, UNSW, Sydney, Australia
- 2Garvan Institute of Medical Research, Sydney, Australia
- 3St Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, Australia
- 4Brain and Mind Centre, Children’s Hospital at Westmead, University of Sydney, Australia
- 5Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, Australia
- 6NSW State Reference Laboratory for HIV, St Vincent’s Centre for Applied Medical Research, Australia
- 7St Vincent’s Hospital Sydney, Australia
- ↵#Correspondence: j.zaunders{at}amr.org.au
Posted July 24, 2022.
High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells
